A team of researchers from the University of Missouri School of Medicine are one step closer to understanding how the uterus repairs itself after menstruation and childbirth, using a process called mesenchymal-epithelial transition (MET).

Chikungunya fever, caused by the Chikungunya virus (CHIKV), has re-emerged as a significant global health concern in recent decades. A notable event was the largest-ever local outbreak in China in 2025, marking a critical juncture in its epidemiology. Although conventional treatment remains predominantly supportive, the integration of traditional Chinese medicine (TCM) offers promising complementary strategies for alleviating both acute symptoms and chronic polyarthralgia. This narrative review aims to consolidate current knowledge on the etiology, pathogenesis, clinical manifestations, and management of Chikungunya fever, with a particular focus on the evidence-based application of TCM. By integrating molecular virology with clinical and epidemiological insights, this review offers a comprehensive perspective on the challenges posed by CHIKV and underscores the strategic imperatives essential for its future management. In conclusion, addressing the expanding threat of CHIKV necessitates a multi-pronged public health strategy that integrates standard clinical and preventive measures with evidence-based TCM therapies, highlighting the urgent need for rigorous clinical trials to globally validate these integrative treatments.

In this study, depressive psychopathology was associated with a greater tendency to be reinforced by a type of social reward on Twitter, in contrast to typical laboratory-based findings of blunted reinforcement learning in depression. These findings suggest potential mechanisms linking social media use to worse mental health or vice versa, and emphasize the importance of studying real-world behavior.

The Bob Woodruff Foundation (BWF) has given a one-year grant to Boston University Chobanian & Avedisian School of Medicine for the continued expansion of the Women Veterans Network (WoVeN), a national, peer support network led by women veterans, for women veterans. Additionally, BWF has provided funding for one year for Strength at Home Couples (SAH-C), a program to enhance intimate relationships and prevent conflict and aggression, including intimate partner violence (IPV), as well as preventing self-harm thoughts and behaviors. Since 2016, the foundation has provided a total of $1.8m to support both programs.

When a child is experiencing a mental health crisis, families increasingly turn to the emergency department for help. While hospitals across Illinois are making progress in caring for these children, they face significant challenges, especially limited access to specialists and long waits for psychiatric care, according to a survey of Illinois emergency departments published in the Journal of American College of Emergency Physicians Open. The surveyed emergency departments also proposed practical solutions, such as investments in mental health staffing, therapeutic activities, and real-time bed tracking for better coordination of psychiatric resources.

Encellin today announced new clinical progress from its ongoing Phase 1 study evaluating its implantable cell therapy platform for people with type 1 diabetes. The company made the announcement in connection with the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting, reporting non-fibrotic engraftment across all seven participants enrolled in the trial, along with host vascularization at the implant site and identification of transplanted islets in multiple participants. The findings build upon interim results first reported in January 2026 and reflect a larger patient cohort, with analysis of the  full clinical dataset ongoing.

The Serum Institute of India (SII) and the non-profit medical research organization Drugs for Neglected Diseases initiative (DNDi) have signed a licensing agreement covering clinical testing and future access for an SII-developed monoclonal antibody treatment (formerly known as VIS513) against dengue. With this agreement finalized, a Phase III clinical trial led by DNDi is expected to begin in the first quarter of 2027 across Malaysia, Thailand, and Brazil, all home to leading public health institutions that are members of the Dengue Alliance, a global partnership of dengue-endemic countries working to develop effective and accessible treatments. 1,000 participants are expected to join the study across the three countries.